文献速递肝病

急性肝衰竭伴脑水肿患者抢先启动连续肾脏替代治疗改善结局:一项随机对照试验

Pre-Emptive Initiation of Continuous Renal Replacement Therapy in Patients With Acute Liver Failure With Cerebral Edema Improves Outcomes: A Randomized Controlled Trial.
PubMed 文献 · Aliment Pharmacol Ther · 2026-06-22

本开放标签试点RCT在急性肝衰竭伴脑水肿患者中比较抢先(12小时内)启动CRRT与仅对血浆置换无应答者启动CRRT的策略。ITT分析显示抢先CRRT显著降低前7天死亡风险(HR 0.12,95%CI 0.02-0.96),28天生存率相当;PP分析中对照组28天死亡率更高(80% vs 46%,HR 3.10,95%CI 1.57-6.12)。

要点

  • 抢先CRRT显著降低ALF伴脑水肿患者前7天死亡风险(HR 0.12)。
  • PP分析中延迟CRRT组28天死亡率显著更高(80% vs 46%)。
  • CRRT每延迟1小时死亡风险增加(HR 1.01,95%CI 1.00-1.02)。

核心结论

  • 在急性肝衰竭伴脑水肿患者中,抢先启动CRRT与治疗性血浆置换具有协同作用,通过快速改善血流动力学、降低血氨和减轻脑水肿减少早期死亡。

研究设计与样本

  • 开放标签试点随机对照试验(RCT),纳入急性肝衰竭伴脑水肿患者,随机分为抢先CRRT组(12小时内启动)和PLEX无应答后启动CRRT组。
  • 患者年龄28.11±10.10岁,56.67%为病毒性,69%为超急性,主要终点为28天生存。

主要发现

  • 第28天总死亡率46%,11%接受肝移植。
  • 方案违背共31例,组2显著更多(55.6% vs 13.3%,p<0.001)。
  • ITT和分段指数回归分析显示抢先CRRT与前7天死亡风险显著降低相关(2.2% vs 17.8%,HR 0.12,95%CI 0.02-0.96),28天生存率相当。
  • PP分析中组2的28天死亡率更高(80% vs 46%,HR 3.10,95%CI 1.57-6.12),且血氨降幅更大、平均动脉压改善更显著、TPE次数更少。
  • CRRT每延迟1小时与死亡风险增加相关(HR 1.01,95%CI 1.00-1.02)。

关键数值与推荐

  • 抢先CRRT组在初始复苏后12小时内启动CRRT;对照组仅对PLEX无应答者启动CRRT。
  • 主要终点为28天生存;ITT分析中前7天死亡风险HR 0.12(95%CI 0.02-0.96)。
  • PP分析中组2 28天死亡率80% vs 46%,HR 3.10(95%CI 1.57-6.12)。
  • CRRT每延迟1小时死亡风险HR 1.01(95%CI 1.00-1.02)。

临床怎么用

  • 对急性肝衰竭伴脑水肿患者,在初始复苏和PLEX基础上考虑12小时内抢先启动CRRT以降低早期死亡。
  • 延迟CRRT与28天死亡率升高相关,应避免不必要的启动延迟。

局限性

  • 为开放标签试点RCT,样本量未在原文摘要中报告。
  • 方案违背较多(共31例),组2显著更多(55.6% vs 13.3%),可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIM: An early initiation of continuous renal replacement therapy (CRRT) for ammonia reduction has shown a reduction in deaths due to cerebral edema (CE) in acute liver failure (ALF); however, there are no controlled trials assessing the same. METHODS: We performed an open-label pilot randomized controlled trial (RCT) on ALF patients with CE. Patients underwent therapeutic plasma-exchange (PLEX) by centrifugal apheresis after initial resuscitation. Group 1 received CRRT initiation within the first 12 h, while Group 2, CRRT was initiated for PLEX non-responders. The primary endpoint was 28-day survival. RESULTS: Patients aged 28.11 ± 10.10 years, 56.67% viral, 69% hyperacute were randomized. At day 28, 46% died and 11% underwent liver transplant. There were a total of 31 protocol violations, significantly more in group 2 (55.6% vs. 13.3%; p < 0.001). On ITT and piece-wise exponential regression analysis, pre-emptive CRRT was associated with a significantly lower hazard of death during the first 7 days (2.2% vs. 17.8% Hazard ratio [HR] 0.12, 95% confidence interval [CI] 0.02-0.96) with comparable survival at 28-days. Notably, higher 28-day mortality was observed on PP analysis in group 2 (80% vs. 46%, HR 3.10, 95% CI 1.57-6.12) with a significantly higher reduction in ammonia and improvement in mean arterial pressure and lower number of sessions of TPE. Each hour delay in CRRT was associated with increased mortality (HR 1.01, 1.00-1.02). CONCLUSION: A pre-emptive initiation of CRRT in ALF patients is synergistic to TPE, reduces early deaths by rapid improvement in hemodynamics, ammonia and cerebral edema (NCT04991259).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Maiwall R, Bajpai M, Pasupuleti SSR, et al. Pre-Emptive Initiation of Continuous Renal Replacement Therapy in Patients With Acute Liver Failure With Cerebral Edema Improves Outcomes: A Randomized Controlled Trial. Aliment Pharmacol Ther. 2026. PMID: 42332991. doi:10.1111/apt.70794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。